Precision BioSciences Management
Management criteria checks 3/4
Precision BioSciences' CEO is Michael Amoroso, appointed in Oct 2021, has a tenure of 3.5 years. total yearly compensation is $4.31M, comprised of 14.7% salary and 85.3% bonuses, including company stock and options. directly owns 1.05% of the company’s shares, worth $549.89K. The average tenure of the management team and the board of directors is 2.5 years and 5.3 years respectively.
Key information
Michael Amoroso
Chief executive officer
US$4.3m
Total compensation
| CEO salary percentage | 14.7% |
| CEO tenure | 3.5yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.5yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
Aug 06
It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks
Jun 23Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?
Mar 14Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?
Dec 08Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles
Sep 02Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash
Aug 16Precision BioSciences Q2 2022 Earnings Preview
Aug 05Precision Bio: Another CAR-T Laggard With No Solid Prospects
May 09Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt
Apr 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$4m | US$635k | US$7m |
| Sep 30 2024 | n/a | n/a | US$11m |
| Jun 30 2024 | n/a | n/a | US$16m |
| Mar 31 2024 | n/a | n/a | -US$20m |
| Dec 31 2023 | US$2m | US$630k | -US$43m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$4m | US$604k | -US$73m |
| Sep 30 2022 | n/a | n/a | -US$76m |
| Jun 30 2022 | n/a | n/a | -US$93m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$6m | US$127k | -US$31m |
Compensation vs Market: Michael's total compensation ($USD4.31M) is above average for companies of similar size in the US market ($USD669.15K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Amoroso (46 yo)
3.5yrs
Tenure
US$4,310,914
Compensation
Mr. Michael Amoroso is Chairman of Abeona Therapeutics LLC. Mr. Amoroso serves as Director, President and Chief Executive Officer of Precision BioSciences, Inc. since October 15, 2021. He serves as Directo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.5yrs | US$4.31m | 1.05% $ 549.9k | |
| Co-Founder & Chief Research Officer | no data | US$1.45m | 0.91% $ 480.6k | |
| CFO & Principal Accounting Officer | 4.3yrs | US$1.89m | 0.82% $ 433.0k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Chief of Staff to CEO & Head of Investor Relations | less than a year | no data | no data | |
| General Counsel & Secretary | 5.8yrs | US$1.51m | 0.24% $ 125.5k | |
| Chief People Officer | 2.9yrs | no data | no data | |
| Chief Development & Business Officer | no data | no data | no data | |
| Senior VP and Head of Chemistry | 2.2yrs | no data | no data | |
| Senior VP & Head of Clinical Development | less than a year | no data | no data |
2.5yrs
Average Tenure
49.5yo
Average Age
Experienced Management: DTIL's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.5yrs | US$4.31m | 1.05% $ 549.9k | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | US$256.47k | no data | |
| Independent Chairman | 5.4yrs | US$214.50k | 0.13% $ 66.4k | |
| Clinical Consultant & Member of Scientific Advisory Board | less than a year | US$909.97k | 0.043% $ 22.5k | |
| Independent Director | 5.1yrs | US$195.75k | 0.11% $ 55.5k | |
| Independent Director | 3.4yrs | US$184.25k | 0.040% $ 21.1k | |
| Independent Director | 2.9yrs | US$185.00k | 0.086% $ 45.5k | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Director | 4yrs | US$182.25k | 0.041% $ 21.3k |
5.3yrs
Average Tenure
67yo
Average Age
Experienced Board: DTIL's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/19 03:29 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Precision BioSciences, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |
| Patrick Trucchio | H.C. Wainwright & Co. |